What are the Challenges in Targeting Immunosuppressive Molecules?
Several challenges exist in targeting immunosuppressive molecules for cancer treatment:
Heterogeneity of the TME: The diversity of cell types and molecules within the TME can make it difficult to identify and target specific immunosuppressive pathways effectively. Toxicity: Therapies that target immunosuppressive molecules can also affect normal tissues, leading to autoimmune side effects and other toxicities. Resistance Mechanisms: Cancer cells can develop resistance to therapies targeting immunosuppressive molecules through various mechanisms, necessitating the development of novel approaches.
